Impact of Elexacaftor/Tezacaftor/Ivacaftor Therapy on the Cystic Fibrosis Airway Microbial Metagenome

The introduction of mutation-specific combination therapy with the cystic fibrosis transmembrane conductance regulator (CFTR) modulators elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) has substantially improved lung function and quality of life of people with cystic fibrosis (CF). Collecting deep co...

Descripción completa

Detalles Bibliográficos
Autores principales: Pallenberg, Sophia T., Pust, Marie-Madlen, Rosenboom, Ilona, Hansen, Gesine, Wiehlmann, Lutz, Dittrich, Anna-Maria, Tümmler, Burkhard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9602284/
https://www.ncbi.nlm.nih.gov/pubmed/36154176
http://dx.doi.org/10.1128/spectrum.01454-22

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9602284/
https://www.ncbi.nlm.nih.gov/pubmed/36154176
http://dx.doi.org/10.1128/spectrum.01454-22

Ejemplares similares